---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: CLXS196X2101"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: CLXS196X2101. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 51 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence/clxs196x2101"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: CLXS196X2101

<a id="heading-3.1.3"></a>

## 3.1.3 CLXS196X2101

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Primary, secondary, and exploratory objectives of single-agent LXS196

> “In this phase I trial, we aimed to evaluate the safety, preliminary efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of LXS196, and to determine the MTD and/or recommended dose for expansion (RDE) of LXS196 as a single agent in patients with MUM.”
> “The primary objectives were to characterise the safety and tolerability and identify the MTD and/or RDE of LXS196 as a single agent in patients with MUM.”
> “Secondary objectives included investigation of the preliminary antitumour activity of LXS196 and evaluation of the PK and PD of LXS196.”
> “Exploratory objectives included assessment of mutations in cancer driver genes by transcriptome and targeted DNA sequencing of baseline tumour biopsies.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.1-2"></a>

#### Registry title and purpose, including a combination part with HDM201

> “A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma”
> “This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.”

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Novartis-sponsored multicenter study initiated on 1 February 2016

> “This was a phase I, first-in human, multicentre, open-label study (NCT02601378), designed and sponsored by Novartis Pharmaceuticals Corporation and initiated on 1 February 2016.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.2-2"></a>

#### Registry protocol number and study dates

| Study characteristic | Quoted record |
| --- | --- |
| Other study ID number | “CLXS196X2101” |
| Study start (actual) | “2016-02-01” |
| Primary completion (actual) | “2022-01-07” |
| Study completion (actual) | “2022-01-07” |

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="topic-3.1.3.2-3"></a>

#### Registry study sites in six countries

| Country | Quoted location | Quoted site |
| --- | --- | --- |
| United States | “New York, New York, United States, 10032” | “Columbia University Medical Center” |
| Australia | “Westmead, New South Wales, Australia, 2145” | “Novartis Investigative Site” |
| France | “Paris, France, 75231” | “Novartis Investigative Site” |
| Netherlands | “Leiden, Netherlands, 2300 RC” | “Novartis Investigative Site” |
| Norway | “Oslo, Norway, 0379” | “Novartis Investigative Site” |
| Spain | “Madrid, Spain, 28050” | “Novartis Investigative Site” |

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Dose escalation guided by a Bayesian logistic regression model, followed by expansion at the recommended dose

> “Dose escalation was guided by safety, PK data and a two-parameter Bayesian Logistic Regression Model (BLRM) [21] employing escalation with overdose control (EWOC) criteria [22].”
> “Upon determination of the MTD/RDE, the expansion part of the study was opened to further evaluate the safety, tolerability, PK and PD of LXS196 at the RDE in patients with MUM.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.3-2"></a>

#### Once-daily schedule followed by a twice-daily schedule

> “Patients were initially treated on a QD schedule (100–1000 mg QD); however, due to toxicities reported at doses ≥500 mg QD, a BID schedule was then tested (200–400 mg BID).”
> “Following determination of the MTD in the QD dosing schedule, a BID schedule was introduced to explore whether alternative dosing may lead to better tolerability of LXS196.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.3-3"></a>

#### Ethics and Good Clinical Practice

> “The study was conducted according to the principles of the Declaration of Helsinki and performed in compliance with Good Clinical Practice.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.3-4"></a>

#### Registry design and status: nonrandomized, open-label, single group; combination part terminated

| Study characteristic | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

> “The combination part of the study was terminated early due to business reasons”

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Adults with biopsy-proven progressive and measurable metastatic disease

> “All patients were aged ≥18 years old and had biopsy-proven MUM with progressive and measurable disease.”
> “Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1 and requested to provide a tumour biopsy at baseline (pre-treatment) and on treatment at day 15 of cycle 1 (C1D15).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.4-2"></a>

#### Treatment-naive or pretreated disease, with no limit on prior lines

> “Patients were either treatment naïve or their disease had progressed (radiologically or clinically) on their most recent therapy. There was no eligibility limit to the number of prior lines of therapy, including PKC inhibitors other than LXS196.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.4-3"></a>

#### Exclusion of cardiac disease, interacting medications, and impaired gastrointestinal function

> “Exclusion criteria included impaired cardiac function or clinically significant cardiac diseases, receipt of concomitant medications known to be strong inducers or inhibitors of cytochrome P450 3A4/5 or known for QT prolongation risk, and impaired GI function that could interfere with absorption of LXS196.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.4-4"></a>

#### Registry: measurable disease definition, central nervous system metastases, and laboratory exclusions

> “Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as >10 mm with CT scan.”
> “Symptomatic or untreated CNS metastases or spinal cord compression. Brain metastasis must be stable with verification by imaging .”
> “AST or ALT > 3 times ULN, AST or ALT > 5 times ULN for patients with liver metastases.”
> “Total bilirubin > 1.5 x ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN.”

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Oral LXS196 once or twice daily in 28-day cycles

> “During dose escalation, patients received oral LXS196 either once daily (QD; 100–1000 mg) or twice daily (BID; 200–400 mg) in 28-day cycles until disease progression, intolerable toxicity or withdrawal of consent (Supplementary Fig. 1).”
> “Dosing was omitted on the second day of the first cycle (C1D2) to allow for longer post-dose sampling in order to better characterise PK.”
> “LXS196 was given on an empty stomach, at least 1 h before or 2 h after a meal.”
> “Patients enroled in the expansion part (n = 12) received LXS196 at the RDE.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.5-2"></a>

#### Dose adjustments and management of hypotension per protocol

> “For patients who did not tolerate their assigned dosing schedule due to a treatment-related AE, dose adjustments were permitted to allow the patient to continue study treatment once the AE had resolved to ≤grade 1.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Dose-limiting Toxicity as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Dose-limiting toxicity period and evaluability for the dose-escalation model

> “The DLT period lasted 28 days after the first dose of LXS196.”
> “A patient was evaluable for the BLRM if the patient took at least 75% of the planned doses during the DLT period or had a DLT.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.6.1-2"></a>

##### Nonclinical findings that anticipated hypotension and gastrointestinal toxicity

> “Data from non-clinical single-dose and 4-week repeated dose toxicology studies in dog, suggested that a decrease in systolic blood pressure may be a potential toxicity observed in patients treated with LXS196. The 4-week toxicology study also identified the GI tract as a potential target of LXS196.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.6.1-3"></a>

##### Safety assessments and adverse event grading

> “Routine safety assessments, including laboratory assessments, physical examinations, vital signs and electrocardiograms (ECGs), were conducted at regular intervals throughout the study and more frequently as needed following patient assessment by the treating physician.”
> “Adverse events (AEs) were assessed continuously according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.6.1-4"></a>

##### Tumor response by local RECIST v1.1 assessment

> “Tumour response was assessed locally by computed tomography (CT) and/or magnetic resonance imaging (MRI) of the chest, abdomen and pelvis, according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 at baseline, on C3D1 and every two cycles thereafter until cycle 11. After 11 cycles of treatment, response was evaluated every three cycles until the end of treatment.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.6.1-5"></a>

##### Registry primary outcomes

| Outcome | Quoted measure | Quoted time frame |
| --- | --- | --- |
| Dose-limiting toxicities | “Incidence of dose limiting toxicities (DLTs) (Dose escalation only)” | “Cycle 1 in dose escalation” |
| Adverse events | “Incidence and severity of adverse events and serious adverse events, including changes in laboratory parameters, vital signs and ECGs graded as per NCI CTCAE version 4.03 (All patients)” | “Continuously throughout the study until 30 days after treatment discontinuation” |
| Dose modifications | “Dose interruptions, reductions and dose intensity” | “Continuously throughout the study until 30 days after treatment discontinuation” |

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="topic-3.1.3.6.1-6"></a>

##### Registry secondary outcomes of efficacy and pharmacodynamics

| Outcome | Quoted measure | Quoted time frame |
| --- | --- | --- |
| Objective response rate | “Overall response rate (ORR) per RECIST version 1.1 criteria” | “From baseline, every 2 cycles until cycle 11, then every 3 cycles afterwards until disease progression or withdrawal of consent up to 12 months” |
| Progression-free survival | “Progression free survival (PFS) per RECIST version 1.1 criteria” | “From baseline, every 2 cycles until cycle 11, then every 3 cycles afterwards until disease progression or withdrawal of consent up to 12 months” |
| Pharmacodynamics | “Modulation of signaling molecules downstream of PKC” | “Baseline and Cycle 1 Day 15” |

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Single-agent part: 68 participants treated, 56 in dose escalation and 12 in expansion

> “A total of 68 patients with MUM were treated with LXS196 in this first-in-human study: 56 in the dose escalation part and 12 in dose expansion (Supplementary Fig. 1).”
> “Patients enroled in dose escalation received doses ranging from 100–1000 mg QD (n = 38) and 200–400 mg BID (n = 18) until the RDE was established.”
> “Patients received LXS196 doses ranging from 100–1000 mg once daily (QD; n = 38) and 200–400 mg twice daily (BID; n = 30).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.7.1-2"></a>

##### Sample size selected for the dose-escalation model, without a formal calculation

> “No hypothesis testing was planned in this study, and therefore, no formal sample size calculation was needed. The sample size was selected to ensure the BLRM had adequate operating characteristics when selecting the MTD/RDE.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.7.1-3"></a>

##### Registry: planned enrollment of the single-agent and HDM201 combination parts and actual enrollment

> “About 68 patients will be enrolled in dose escalation and expansion”
> “about 44 patients to be enrolled in dose escalation and expansion”

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

| Study characteristic | Quoted record |
| --- | --- |
| Enrollment (actual), single-agent and HDM201 combination parts | “107” |

Source: [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

##### Population evaluable for maximum tolerated dose determination

> “Fifty-five patients were evaluable for MTD/RDE determination, with one patient excluded from the DLT analysis due lack of sufficient exposure to study treatment during cycle 1.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.7.2-2"></a>

##### Response population including participants without post-baseline assessment

> “Two patients did not have post-baseline tumour assessments due to clinical disease progression before the first scheduled assessment. Hence, the BOR is unknown per RECIST 1.1, however, they are included in the denominator for ORR and DCR calculations.”
> “Estimate [95% CI] for ORR and DCR were obtained using Clopper and Pearson’s method.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.7.2-3"></a>

##### Descriptive statistics and Kaplan-Meier estimation

> “Data are presented using descriptive statistics and visualisations. Continuous variables are described with the mean and range. Categorical variables are described using counts and percentages. PFS is described using the Kaplan–Meier (KM) method.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.7.2-4"></a>

##### Pharmacodynamic analysis restricted to the once-daily schedule

> “PD analysis was not performed on tumour samples from patients who received LXS196 on a BID schedule.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### Final data cutoff of 7 January 2022: discontinuation in the once-daily schedule

> “At the final data cut-off date (7 January 2022), all patients in the QD schedule had discontinued treatment due to disease progression.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.1-2"></a>

##### Final data cutoff of 7 January 2022: duration of exposure

> “As of the final data cut-off date (7 January 2022), a total of 68 patients had been treated with LXS196 and the median duration of exposure was 3.71 months (range: 1.81–15.28) and 4.6 months (range: 0.33–58.32) for patients in the QD and BID regimens, respectively.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.1-3"></a>

##### Single discontinuation due to an adverse event

> “The only AE leading to discontinuation of LXS196 was an SAE of grade 3/4 hepatic failure in a patient treated in the BID schedule with known liver metastases and CTCAE grade 2 transaminases at study entry. The event was suspected to be related to underlying disease progression but was not confirmed by radiological assessment.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

##### Baseline characteristics by schedule and at the recommended dose for expansion

| Characteristic | All QD, n = 38 | All BID, n = 30 | 300 mg BID (RDE), n = 18 | All patients, N = 68 |
| --- | --- | --- | --- | --- |
| Median age, years (range) | “55 (26–76)” | “57 (33–78)” | “56.5 (38–76)” | “56 (26–78)” |
| Male, n (%) | “22 (57.9)” | “14 (46.7)” | “7 (38.9)” | “36 (52.9)” |
| Female, n (%) | “16 (42.1)” | “16 (53.3)” | “11 (61.1)” | “32 (47.1)” |
| ECOG performance status 0, n (%) | “37 (97.4)” | “25 (83.3)” | “14 (77.8)” | “62 (91.2)” |
| ECOG performance status 1, n (%) | “1 (2.6)” | “5 (16.7)” | “4 (22.2)” | “6 (8.8)” |
| Lactate dehydrogenase above ULN, n (%) | “23 (60.5)” | “15 (50.0)” | “8 (44.4)” | “38 (55.9)” |
| No prior systemic therapy, n (%) | “3 (7.9)” | “6 (20.0)” | “6 (33.3)” | “9 (13.2)” |
| One prior systemic therapy, n (%) | “19 (50.0)” | “18 (60.0)” | “9 (50.0)” | “37 (54.4)” |
| Two prior systemic therapies, n (%) | “12 (31.6)” | “2 (6.7)” | “2 (11.1)” | “14 (20.6)” |
| More than two prior systemic therapies, n (%) | “4 (10.5)” | “4 (13.3)” | “1 (5.6)” | “8 (11.8)” |
| Any prior immunotherapeutic agent, n (%) | “22 (57.9)” | “14 (46.7)” | “4 (22.2)” | “36 (52.9)” |
| Prior pembrolizumab, n (%) | “11 (28.9)” | “10 (33.3)” | “4 (22.2)” | “21 (30.9)” |
| Liver-only metastases, n (%) | “13 (34.2)” | “14 (46.7)” | “9 (50.0)” | “27 (39.7)” |
| Liver and other metastases, n (%) | “20 (52.6)” | “13 (43.3)” | “7 (38.9)” | “33 (48.5)” |
| Maximum target lesion diameter, median mm (range) | “39 (11–126)” | “35.5 (11–201)” | “40 (11–201)” | “36 (11–201)” |

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.2-2"></a>

##### Demographics, metastatic sites, and prior therapy

> “The median age was 56.0 years, 36 (52.9%) were male, and most (n = 62; 91.2%) had a performance status of 0. The majority of patients (n = 60; 88.2%) had liver metastases, 27 of whom (14 in the BID schedule and 13 in the QD schedule) had only liver metastases and no other sites of disease at study entry.”
> “Other reported metastatic sites with an incidence of at least 10% included lung (n = 18, 26.5%), bone (n = 13, 19.1%), lymph node (n = 8, 11.8%) and skin (n = 7, 10.3%).”
> “Overall, 59 patients (86.8%) had received prior systemic therapy; the majority having received either one (n = 37, 54.4%) or two prior regimens (n = 14, 20.6%).”
> “The majority of patients (n = 31, 45.6%) had PD as the best overall response (BOR) to their last prior therapy and in these patients, the median time from initiation to discontinuation of last prior therapy was 63 days (range: 14–515).”
> “No patients had received prior tebentafusp.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.2-3"></a>

##### GNAQ, GNA11, and BAP1 mutations in baseline tumor biopsies

> “Mutations in the GNAQ and GNA11 genes are tabulated (Supplementary Table 5A); of the 48 patients assessed, 28 were mutant in GNA11 (of which 22 had allele Q209L and 6 had R183C), 16 were mutant in GNAQ (of which 13 had allele Q209P, two Q209L, and one R183Q), and 4 were not called mutant in either gene as the allele fraction was below the limit of detection.”
> “BAP1 mutations resulting in a protein coding change were detected in 44% (21/48) of patients (Supplementary Table 5B).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

##### Best overall response and progression-free survival by schedule and at the recommended dose for expansion

| Outcome | All QD, n = 38 | All BID, n = 30 | 300 mg BID (RDE), n = 18 | All patients, N = 68 |
| --- | --- | --- | --- | --- |
| Complete response, n (%) | “0” | “1 (3.3)” | “0” | “1 (1.5)” |
| Partial response, n (%) | “2 (5.3)” | “3 (10.0)” | “2 (11.1)” | “5 (7.4)” |
| Stable disease, n (%) | “27 (71.1)” | “18 (60.0)” | “12 (66.7)” | “45 (66.2)” |
| Progressive disease, n (%) | “9 (23.7)” | “6 (20.0)” | “3 (16.7)” | “15 (22.1)” |
| Objective response rate, 95% CI | “[0.6–17.7]” | “[3.8–30.7]” | “[1.4–34.7]” | “[3.3–18.2]” |
| Disease control rate, n (%) | “29 (76.3)” | “22 (73.3)” | “14 (77.8)” | “51 (75.0)” |
| Disease control rate, 95% CI | “[59.8–88.6]” | “[54.1–87.7]” | “[52.4–93.6]” | “[63–84.7]” |
| Median progression-free survival, months (95% CI) | “3.5 (3.5–5.4)” | “4.1 (3.5–7.2)” | “3.7 (2.1–5.4)” | “3.6 (3.5–5.4)” |
| Progression-free survival rate at 4 months, % (95% CI) | “36.8 (22.0–51.8)” | “50.0 (31.3–66.1)” | “44.4 (21.6–65.1)” | “42.6 (30.8–54.0)” |
| Progression-free survival rate at 6 months, % (95% CI) | “26.3 (13.7–40.8)” | “33.3 (17.5–50.0)” | “27.8 (10.1–48.9)” | “29.4 (19.1–29.2)” |
| Progression-free survival rate at 12 months, % (95% CI) | “0.0 (NE–NE)” | “26.7 (12.6–43.0)” | “22.2 (6.9–42.9)” | “11.8 (5.5–20.6)” |

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.3-2"></a>

##### All participants: response, duration of response, and duration of stable disease

> “Clinical activity was observed in 6/66 (9.1%) evaluable patients achieving response (CR/PR), with a median duration of response of 10.15 months (range: 2.99–41.95); 45/66 had stable disease (SD) per RECIST v1.1.”
> “The median duration of response for all patients with a RECIST response (n = 6) was 10 months (2.99–41.95) and median duration of SD (n = 45) was 5.32 months (2.07–30.23).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.3-3"></a>

##### Twice-daily schedule and the recommended dose for expansion of 300 mg twice daily: response

> “The ORR in the BID schedule was 13.3% (95% CI: 3.8–30.7) and the disease control rate (DCR) was 73.3% (95% CI: 54.1–87.7) (Table 3).”
> “Of the 18 evaluable patients treated at the RDE of 300 mg BID, 2 (11.1%) had a BOR of PR and 12 (66.7%) had SD (including 3 patients with >30% tumour reduction/unconfirmed PR).”
> “The ORR at the RDE was 11.1% (95% CI: 1.4–34.7) and the DCR was 77.8% (95% CI: 52.4–93.6) (Fig. 3).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.3-4"></a>

##### Progression-free survival in all participants, the twice-daily schedule, and at the recommended dose for expansion

> “No patients were censored and 100% of PFS events were reported as of the data cut-off date. Of the 68 events, 66 had disease progression and 2 patients had died. The estimated median PFS was 3.6 months (95% CI: 3.5–5.4) and the estimated PFS rate at 6 months by the KM method was 29.4% (95% CI: 19.1–40.4).”
> “In the BID schedule, the estimated median PFS was 4.1 months (95% CI: 3.5–7.2) and the estimated PFS rate at 6 months by the KM method was 33.3% (95% CI: 17.5–50).”
> “At the RDE of 300 mg BID, the estimated median PFS was 3.7 months (95% CI: 2.1–5.4) and the estimated PFS rate at 6 months by the KM method was 27.8% (95% CI: 10.1–48.9) (Table 3).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.3-5"></a>

##### Response by GNAQ or GNA11 mutation status

> “No association of GNAQ/GNA11 mutation status with patient response was observed (Fig. 3).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.3-6"></a>

##### Comparison by the authors with the first-generation PKC inhibitor AEB071

> “Regarding efficacy, across all doses tested the ORR was 8.8% with LXS196 versus 3% with AEB071, and 67% of patients had SD as their best response with LXS196 versus 50% with AEB071 (median duration of SD: 5.32 versus 3.75 months, respectively). The estimated median PFS was similar at 3.6 months (95% CI: 3.5–5.4) with LXS196 versus 3.5 months (95% CI: 2.5–3.6) with AEB071.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.3-7"></a>

##### Complete response at month 31 reported by the sponsor

> “Confirmed Complete Response observed at month 31 in one patient previously reported with confirmed Partial Response in the ongoing IDE196 monotherapy clinical trial conducted by Novartis (ClinicalTrials.gov Identifier: NCT02601378)”

Source: [IDEAYA Biosciences press release, End-of-Phase 1 meeting with FDA (2019)](https://media.ideayabio.com/2019-10-31-IDEAYA-Biosciences-Reports-End-of-Phase-1-Meeting-with-FDA-for-IDE196-Confirms-Acceptability-of-Single-Arm-Trial-Design-for-Potential-Phase-2-Registration-Enabling-Study-in-Metastatic-Uveal-Melanoma)

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

##### Dose-limiting toxicities and declaration of the maximum tolerated doses and recommended dose for expansion

> “First cycle dose-limiting toxicities (DLTs) were observed in 7/38 (18.4%) QD and 2/17 (11.8%) BID patients. Hypotension was the most common DLT, occurring at doses ≥500 mg/day, and manageable with LXS196 interruption and dose reduction.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

> “The MTDs were declared at 500 mg QD and 400 mg BID, based on the BLRM and EWOC principles.”
> “Following the BLRM recommendation guided by EWOC and review of all available safety and PK data, the RDE was declared at 300 mg BID (Supplementary Fig. 1).”
> “Of the 55 patients evaluable for MTD/RDE determination, DLTs were observed in nine (16.4%) patients (seven patients treated in the QD schedule and two patients in the BID schedule) (Table 2A). The most common DLT was hypotension (n = 6; 10.9%).”
> “Other DLTs included nausea and vomiting, neutropenia and generalised oedema (one patient each; 1.8%). GI-related DLTs resolved with temporary interruption of study drug and treatment with anti-emetics.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.5-2"></a>

##### Hypotension as a dose-limiting toxicity: timing, presentation, and resolution

> “In the QD schedule, hypotension leading to drug interruption and subsequent dose reduction occurred in five patients treated at doses ≥500 mg (two grade 3 events at 500 mg QD, one grade 4 event at 800 mg QD, one grade 4 and one grade 2 event at 1000 mg QD). These events most commonly occurred within 1 to 4 h after the first or second dose and were sometimes accompanied by a transient loss of consciousness with preceding dizziness and sweating.”
> “Most events resolved within minutes, some within 4 h, with an infusion of intravenous fluids and 2 patients experienced recurrence of hypotension with 1 patient requiring further LXS196 dose reduction.”
> “One DLT of grade 3 hypotension was reported in a patient treated at the highest BID dose tested (400 mg BID).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.5-3"></a>

##### Adverse events suspected to be related to LXS196 by schedule and at the recommended dose for expansion

| Preferred term | All QD, n = 38, all grades | All QD, grade 3 or higher | All BID, n = 30, all grades | All BID, grade 3 or higher | 300 mg BID (RDE), n = 18, all grades | 300 mg BID (RDE), grade 3 or higher | All patients, N = 68, all grades | All patients, grade 3 or higher |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Participants with at least 1 adverse event, n (%) | “35 (92.1)” | “11 (28.9)” | “28 (93.3)” | “6 (20.0)” | “17 (94.4)” | “2 (11.1)” | “63 (92.6)” | “17 (25.0)” |
| Nausea, n (%) | “26 (68.4)” | “1 (2.6)” | “19 (63.3)” | “0” | “14 (77.8)” | “0” | “45 (66.2)” | “1 (1.5)” |
| Diarrhoea, n (%) | “15 (39.5)” | “0” | “16 (53.3)” | “1 (3.3)” | “11 (61.1)” | “1 (5.6)” | “31 (45.6)” | “1 (1.5)” |
| Vomiting, n (%) | “12 (31.6)” | “1 (2.6)” | “9 (30.0)” | “0” | “7 (38.9)” | “0” | “21 (30.9)” | “1 (1.5)” |
| Alanine aminotransferase increased, n (%) | “7 (18.4)” | “2 (5.3)” | “8 (26.7)” | “2 (6.7)” | “5 (27.8)” | “1 (5.6)” | “15 (22.1)” | “4 (5.9)” |
| Hypotension, n (%) | “8 (21.1)” | “5 (13.2)” | “7 (23.3)” | “1 (3.3)” | “3 (16.7)” | “0” | “15 (22.1)” | “6 (8.8)” |
| Fatigue, n (%) | “10 (26.3)” | “0” | “4 (13.3)” | “0” | “3 (16.7)” | “0” | “14 (20.6)” | “0” |
| Asthenia, n (%) | “6 (15.8)” | “0” | “7 (23.3)” | “0” | “4 (22.2)” | “0” | “13 (19.1)” | “0” |
| Aspartate aminotransferase increased, n (%) | “5 (13.2)” | “2 (5.3)” | “6 (20.0)” | “2 (6.7)” | “3 (16.7)” | “1 (5.6)” | “11 (16.2)” | “4 (5.9)” |
| Dry skin, n (%) | “2 (5.3)” | “0” | “6 (20.0)” | “0” | “4 (22.2)” | “0” | “8 (11.8)” | “0” |
| Rash, n (%) | “3 (7.9)” | “0” | “5 (16.7)” | “0” | “4 (22.2)” | “0” | “8 (11.8)” | “0” |
| Blood creatinine increased, n (%) | “2 (5.3)” | “0” | “5 (16.7)” | “0” | “2 (11.1)” | “0” | “7 (10.3)” | “0” |
| Constipation, n (%) | “4 (10.5)” | “0” | “3 (10.0)” | “0” | “1 (5.6)” | “0” | “7 (10.3)” | “0” |

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.5-4"></a>

##### Grade 3 or higher serious adverse events regardless of relationship, by schedule

| Preferred term | All QD, n = 38 | 300 mg BID (RDE), n = 18 | All BID, n = 30 | All patients, N = 68 |
| --- | --- | --- | --- | --- |
| Participants with at least 1 serious adverse event, n (%) | “7 (18.4)” | “5 (27.8)” | “7 (23.3)” | “14 (20.6)” |
| Hypotension, n (%) | “5 (13.2)” | “0” | “1 (3.3)” | “6 (8.8)” |
| Pneumonia, n (%) | “2 (5.3)” | “1 (5.6)” | “1 (3.3)” | “3 (4.4)” |

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.5-5"></a>

##### Adverse events regardless of relationship, serious adverse events, and tolerability of the two schedules

> “The majority of patients (n = 66; 97.1%) experienced an AE regardless of study drug relationship during the study; 29 (42.6%) of these patients experienced AEs of grade 3/4 (Supplementary Table 2).”
> “The most frequent AEs with LXS196 (all grades, all doses, both schedules) were nausea (n = 48; 70.6%), diarrhoea (n = 37; 54.4%), vomiting (n = 26; 38.2%), fatigue (n = 19; 27.9%), increased alanine aminotransferase (ALT, n = 18; 26.5%), constipation (n = 17; 25%), asthenia (n = 15; 22.1%) and hypotension (n = 15; 22.1%).”
> “The most frequent AEs of grade ≥3, regardless of study drug relationship, were hypotension (n = 6; 8.8%), increased aspartate aminotransferase (AST, n = 5; 7.4%) and increased ALT (n = 4; 5.9%).”
> “Serious AEs (SAEs) were observed in 14 (20.6%) patients, and all were grade 3/4; the most frequent were hypotension (n = 6; 8.8%) and pneumonia (n = 3; 4.4%) (Table 2C). BID appeared to be better tolerated than QD dosing, with fewer treatment-related grade 3/4 AEs and treatment-related SAEs. Grade 3/4 hypotension was more common in the QD versus the BID groups (13.2% versus 3.3%).”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.8.5-6"></a>

##### Interruptions and dose reductions as described by the authors

> “Overall, LXS196 was generally well tolerated as a single agent, with the majority of patients not requiring interruption of LXS196 or a dose reduction from their assigned dose level.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary

CLXS196X2101 is a nonrandomized, open-label, single-group phase 1 study of LXS196 (darovasertib) as a single agent, without crizotinib. No hypothesis testing was planned and no formal sample size calculation was made; data are presented descriptively. Of the 68 participants, 59 (86.8%) had received prior systemic therapy, and none had received prior tebentafusp. Participants were treated across once-daily doses of 100 to 1000 mg (n = 38) and twice-daily doses of 200 to 400 mg (n = 30), and 18 were evaluable at the recommended dose for expansion of 300 mg twice daily. Tumour response was assessed locally per RECIST v1.1. The ORR denominator differs between the text (6 of 66 evaluable participants, 9.1%) and the results table, which includes 2 participants without post-baseline assessment in a denominator of 68; the 95% CI of the 6-month PFS rate in all participants is 19.1 to 40.4 in the text and 19.1 to 29.2 in the table. Pharmacodynamic analysis was not performed on tumour samples from the twice-daily schedule, the authors note that the C1D15 biopsy timepoint might be too late to observe transient changes, and the sequencing panel did not include CYSLTR2 and PLCB4. The combination part with HDM201 was terminated early for business reasons. No quality-of-life or patient-reported outcome results were reported; the registry outcomes cover dose-limiting toxicities, adverse events, dose modifications, ORR, PFS, and pharmacodynamics.

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/); [ClinicalTrials.gov NCT02601378](https://clinicaltrials.gov/study/NCT02601378)

<a id="topic-3.1.3.9-2"></a>

#### Exploratory phase 1 design without formal statistical testing

> “Owing to the exploratory nature of this phase I study, formal statistical tests were not planned to be performed.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.9-3"></a>

#### Genes not covered by the sequencing panel

> “The genes CYSLTR2 and PLCB4 were not included in the sequencing panel.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-3.1.3.9-4"></a>

#### Timing of on-treatment biopsies for pharmacodynamic assessment

> “There are several possible explanations for the lack of correlation between reductions in pMARKCS/pPKCd and clinical activity. One possibility is that the PKC signalling pathway is highly sensitive to LXS196 exposure, and a C1D15 timepoint might be too late to observe transient changes.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
